WallStSmart

Amazon.com Inc (AMZN)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amazon.com Inc generates 1121% more annual revenue ($716.92B vs $58.74B). AZN leads profitability with a 17.4% profit margin vs 10.8%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).

AMZN

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 7.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.33

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMZNSignificantly Overvalued (-95.3%)

Margin of Safety

-95.3%

Fair Value

$106.12

Current Price

$211.71

$105.59 premium

UndervaluedFair: $106.12Overvalued
AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$185.78

$120.29 discount

UndervaluedFair: $306.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMZN3 strengths · Avg: 9.7/10
Market CapQuality
$2.20T10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$14.94B10/10

Generating 14.9B in free cash flow

Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AMZN3 concerns · Avg: 3.7/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

P/E RatioValuation
28.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMZN

The strongest argument for AMZN centers on Market Cap, Free Cash Flow, Return on Equity. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AMZN

The primary concerns for AMZN are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

AMZN carries more volatility with a beta of 1.42 — expect wider price swings.

AMZN is growing revenue faster at 13.6% — sustainability is the question.

AMZN generates stronger free cash flow (14.9B), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (66/100 vs 59/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amazon.com Inc

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Amazon.com, Inc. is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence. It is one of the Big Five companies in the U.S. information technology industry, along with Google, Apple, Microsoft, and Facebook. The company has been referred to as one of the most influential economic and cultural forces in the world, as well as the world's most valuable brand.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?